Babcock & Wilcox Enterprises Declares Preferred Stock Dividend
The company approved a dividend of $0.484375 per share on its 7.75% Series A Cumulative Perpetual Preferred Stock.
Stocks · News reference
Jim Cramer: 'You Could Make Some Money With This 5.6% Yield'
Jim Cramer likes Babcock & Wilcox and Smithfield Foods. He also advises taking some profits on BillionToOne, and calls Eton Pharma a winner.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Eton Pharmaceuticals Announces Preliminary Results for ET-700 Pilot Study
Eton Pharmaceuticals released preliminary results from a pilot study of ET-700, an investigational extended-release zinc acetate formulation for Wilson disease, showing improved tolerability compared to GALZIN.
Eton Q3 Earnings Call Highlights Growth and Pipeline Expansion
Eton Pharmaceuticals exceeded expectations in Q3 2026 with revenues of $57.9M (158% YoY growth) and raised full-year revenue guidance to over $175M with adjusted EBITDA margins above 40%. The company achieved its $200M annualized revenue run-rate target five quarters ahead of schedule, driven primarily by HEMANGEOL sales. Eton is preparing for an April 2027 LIBERVANT launch and advancing its pipeline including ASN-001 and ET-900.
Eton Pharmaceuticals to Present at 2026 Jefferies Global Healthcare Conference
Eton Pharmaceuticals announced that its executive leadership team will present at the 2026 Jefferies Global Healthcare Conference in London in November 2026.
Eton Pharmaceuticals Reports Third Quarter 2026 Financial Results
Eton Pharmaceuticals reported record third-quarter 2026 revenue of $57.9 million, a 158% year-over-year increase, and raised its full-year 2026 financial guidance.
8-K filing — Eton Pharmaceuticals, Inc. (ETON)
Filed: 2026-11-05 AccNo: 0001710340-26-000006 Size: 504 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits